NASDAQ:ACST Acasti Pharma (ACST) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free ACST Stock Alerts $2.90 -0.03 (-1.02%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.77▼$3.1350-Day Range$2.85▼$3.4852-Week Range$1.72▼$3.84Volume3,831 shsAverage Volume15,542 shsMarket Capitalization$27.26 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Acasti Pharma alerts: Email Address Acasti Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside106.9% Upside$6.00 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.44) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.28 out of 5 starsMedical Sector505th out of 914 stocksPharmaceutical Preparations Industry220th out of 418 stocks 3.5 Analyst's Opinion Consensus RatingAcasti Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcasti Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.06% of the float of Acasti Pharma has been sold short.Short Interest Ratio / Days to CoverAcasti Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acasti Pharma has recently increased by 171.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcasti Pharma does not currently pay a dividend.Dividend GrowthAcasti Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACST. Previous Next 1.7 News and Social Media Coverage News SentimentAcasti Pharma has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Acasti Pharma this week, compared to 0 articles on an average week.Search Interest4 people have searched for ACST on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acasti Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders13.51% of the stock of Acasti Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.08% of the stock of Acasti Pharma is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Acasti Pharma are expected to grow in the coming year, from ($1.44) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acasti Pharma is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acasti Pharma is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcasti Pharma has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Acasti Pharma Stock (NASDAQ:ACST)Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Read More ACST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACST Stock News HeadlinesApril 26, 2024 | americanbankingnews.comAcasti Pharma (NASDAQ:ACST) Stock Price Passes Above 200 Day Moving Average of $2.74April 26, 2024 | americanbankingnews.comAcasti Pharma Inc. (NASDAQ:ACST) Short Interest UpdateApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 18, 2024 | americanbankingnews.comAcasti Pharma (NASDAQ:ACST) Stock Passes Above 200-Day Moving Average of $2.73December 14, 2023 | morningstar.comAcasti Pharma Inc Class ADecember 13, 2023 | finance.yahoo.comAcasti to Participate in Upcoming San Francisco Investor Conferences in January 2024November 13, 2023 | finance.yahoo.comAcasti Announces Second Quarter 2024 Financial Results and Business HighlightsOctober 18, 2023 | markets.businessinsider.comOptimistic Outlook for Acasti Pharma’s GTX-104: Assessing Buy Rating and Potential Impact on Aneurysmal Subarachnoid Hemorrhage TreatmentApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.October 4, 2023 | finance.yahoo.comAcasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)September 27, 2023 | seekingalpha.comAcasti announces $7.5M private placement equity fundingJuly 12, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Acasti Pharma (ACST), ImmunoPrecise Antibodies (IPA)July 7, 2023 | markets.businessinsider.comAcasti Pharma: Reverse Stock Split To Become Effective July 10July 7, 2023 | finance.yahoo.comAcasti Pharma Announces 1-for-6 Reverse Stock SplitJuly 5, 2023 | finance.yahoo.comAcasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023June 23, 2023 | msn.comRecap: Acasti Pharma Q4 EarningsMay 10, 2023 | finance.yahoo.comWe're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash WiselyMay 8, 2023 | finance.yahoo.comAcasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025April 4, 2023 | finance.yahoo.comAcasti Announces Appointment of Prashant Kohli as CEOApril 4, 2023 | finance.yahoo.comAcasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the INDMarch 30, 2023 | finance.yahoo.comWhen Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit?March 30, 2023 | finance.yahoo.comAcasti Pharma Inc. Announces the Resignation of a DirectorMarch 13, 2023 | finance.yahoo.comAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture ExchangeFebruary 13, 2023 | msn.comAcasti Pharma's Earnings OutlookFebruary 7, 2023 | finance.yahoo.comAcasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023January 25, 2023 | finance.yahoo.comAcasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price RuleJanuary 17, 2023 | finance.yahoo.comAcasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day PodcastSee More Headlines Receive ACST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/12/2024Today4/27/2024Next Earnings (Estimated)6/28/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACST CUSIPN/A CIK1444192 Webwww.acastipharma.com Phone45-0686-4555Fax45-0687-2272Employees32Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+106.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($5.0792) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-13.18% Return on Assets-11.32% Debt Debt-to-Equity RatioN/A Current Ratio15.19 Quick Ratio15.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.14 per share Price / Book0.32Miscellaneous Outstanding Shares9,400,000Free Float8,129,000Market Cap$27.26 million OptionableNot Optionable Beta1.49 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Prashant Kohli (Age 52)CEO & Director Comp: $358.41kMr. Robert J. DelAversano CPA (Age 52)Principal Financial & Accounting Officer Dr. R. Loch MacDonald M.D. (Age 62)Ph.D., Member of Scientific Advisory Board & Chief Medical Officer Mr. Amresh Kumar Ph.D. (Age 44)VP of Program Management Ms. Carrie D'Andrea (Age 52)VP of Clinical Operations Key CompetitorsForte BiosciencesNASDAQ:FBRXSol-Gel TechnologiesNASDAQ:SLGLQilian International Holding GroupNASDAQ:QLIDURECTNASDAQ:DRRXIterum TherapeuticsNASDAQ:ITRMView All CompetitorsInsidersVimal KavuruBought 676,371 shares on 9/25/2023Total: $1.25 M ($1.85/share)Donald OldsBought 381 shares on 8/31/2023Total: $781.05 ($2.05/share)View All Insider Transactions ACST Stock Analysis - Frequently Asked Questions Should I buy or sell Acasti Pharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACST shares. View ACST analyst ratings or view top-rated stocks. What is Acasti Pharma's stock price target for 2024? 1 Wall Street research analysts have issued twelve-month target prices for Acasti Pharma's shares. Their ACST share price targets range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 106.9% from the stock's current price. View analysts price targets for ACST or view top-rated stocks among Wall Street analysts. How have ACST shares performed in 2024? Acasti Pharma's stock was trading at $2.89 at the beginning of 2024. Since then, ACST stock has increased by 0.3% and is now trading at $2.90. View the best growth stocks for 2024 here. Are investors shorting Acasti Pharma? Acasti Pharma saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 3,800 shares, an increase of 171.4% from the March 31st total of 1,400 shares. Based on an average daily trading volume, of 25,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the shares of the stock are short sold. View Acasti Pharma's Short Interest. When is Acasti Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, June 28th 2024. View our ACST earnings forecast. How were Acasti Pharma's earnings last quarter? Acasti Pharma Inc. (NASDAQ:ACST) posted its quarterly earnings data on Monday, February, 12th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02. When did Acasti Pharma's stock split? Acasti Pharma shares reverse split on the morning of Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS). How do I buy shares of Acasti Pharma? Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACST) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
